If you are not happy with the results below please do another search
The British-Swedish company on Tuesday laid out an ambitious plan to boost growth in its existing oncology, biopharma and rare disease portfolios, as well as launch 20 new medicines before the end of the decade.
Med Ad News caught up with Bauman ahead of the agency’s announcement, and he was clear in his enthusiasm not only for imre’s creative legacy but also the agency’s culture and people, many of whom Bauman has worked with or known professionally throughout his career. “We’re putting the band back together. Anna [Kotis, imre president] and I have a long-time partnership, going almost 20 years back to when we were partners. Scott Tucker [imre’s chief client officer] and I also worked together.”
The regulator approved two interchangeable biosimilars to Regeneron’s Eylea, providing additional competition for the pharma’s blockbuster as key patent protections are set to expire.
“We want to introduce Precision AQ as a team of advisors, experts, and creators to sit in the room with our clients to partner, looking at access as a continuum,” President Doug Fulling told Med Ad News. “This has been 10 years in the making. We started the rebrand process six months ago, but the reason that we’re doing this now is we want to simplify our North Star and where we’re going in the marketplace.”
The drug, called depemokimab, showed “significant and meaningful reductions” in asthma attacks for patients with eosinophilic asthma, the company stated.
Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. This represents a first collaboration of its kind within the pharma and life sciences industries.
In recognition of Clinical Trials Day, The Trial for #ClinicalEquality –a longstanding and widely celebrated initiative from FCB Health New York, an IPG Health company – continues the fight to increase equity in clinical trials with the next phase of its campaign entitled, “Worth Less.”
Earlier this month, Neuralink said tiny wires implanted in the brain of its first patient had pulled out of position. Reuters reported last week, citing sources, the company knew from animal testing that the wires might retract.
H4B Chelsea President Violet Aldaia was recently elected the new board chair of the Coalition for Healthcare Communication (CHC). Med Ad News spoke with Aldaia to get a quick take on the issues she feels are most important for CHC to address this year.
Pfizer’s Wyeth unit notched a legal victory over AstraZeneca on Friday as a federal jury found the British-Swedish company violated two key patents in developing and marketing its lung cancer drug Tagrisso.